In the BioHarmony Drug Report Database
Ravulizumab-cwvz
Ultomiris (ravulizumab) is an antibody pharmaceutical. Ravulizumab was first approved as Ultomiris on 2018-12-21. It is used to treat atypical hemolytic uremic syndrome in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. It is known to target complement C5.
Trade Name
|
Ultomiris |
|---|---|
Common Name
|
ravulizumab |
ChEMBL ID
|
CHEMBL3989986 |
Indication
|
atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
